FSFurkat Sobirov

Furkat Sobirov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Furkat Sobirov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes

    by Amir Arsalan Ghahari, Ainur Sadykova, Salim Davlatov, Mukaddas Xusanova, Gulrukh Indiaminova, Furkat Sobirov, Mirzamakhmud Shadmanov, Umidjon Maxamatov, Patkhiddin Nishonov, Seyed Davar Siadat

    Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon‐level associations are often inconsistent across studies and disease contexts. This review advances an effector‐centered framework to explain how A. muciniphila acts through host‐facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus‐associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell‐envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota–gut–brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll‐like receptor (TLR) signaling, but mucus‐active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole‐cell effects: in high‐fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon‐like peptide 1 (GLP‐1) release. Key gaps include physiological dose realism, equivalence across colony‐forming units (CFU) and protein or vesicle doses, strain and culture‐condition dependence of effector expression, and limited human data for brain‐relevant endpoints. Effector‐defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose‐response validation, and mechanism‐linked biomarkers.